Oncimmune Holdings PLC Director/PDMR Shareholding
11 November 2024 - 10:15PM
RNS Regulatory News
RNS Number : 7323L
Oncimmune Holdings PLC
11 November 2024
Oncimmune Holdings plc
("Oncimmune" or the
"Company")
Director/PDMR
Shareholding
Oncimmune Holdings plc (AIM: ONC.L),
a leading autoantibody profiling company providing research
services to the pharmaceutical and biotechnology industries to
enable the delivery of precision medicine, announces the
acquisition of Subscription Shares by certain board members, and
waiver and issue of share options to certain Persons Discharging
Managerial Responsibilities pursuant to the Fundraising, as
detailed in the Company's announcement dated 18 October 2024 (the
"Fundraising
Announcement"). A summary of the subscribing
Directors' shareholdings are as follows:
Subscription for ordinary
shares
|
PDMR
|
Previous
holding of Ordinary Shares
|
Number of
Subscription Shares purchased
|
Resultant
shareholding
|
Resulting
% of Enlarged Share Capital
|
|
Alistair Macdonald
|
55,555
|
100,000
|
155,555
|
0.14
|
|
Martin Gouldstone
|
36,023
|
66,667
|
102,690
|
0.09
|
|
John Goold
|
1,150,000
|
333,333
|
1,483,333
|
1.33
|
Waiver of options
|
PDMR
|
Number of
options waived
|
Date of
grant of options waived
|
Exercise
price of options waived
|
Resulting
number of options held
|
|
Martin Gouldstone
|
589,971
|
7 November
2023
|
£0.1695
|
0
|
|
Martin Hudson
|
105,263
|
8 December
2023
|
£0.266
|
0
|
Grant of options
|
PDMR
|
Number of
options granted
|
Exercise
price
|
% of
Enlarged Share Capital
|
|
|
Martin Gouldstone
|
5,588,661
|
£0.15
|
5%
|
|
|
Martin Hudson
|
3,353,197
|
£0.15
|
3%
|
|
The new options are subject to
performance conditions relating to the Company's EBITDA and share
price performance, further detail of which is set out in the
Fundraising Announcement.
Unless otherwise defined, all
capitalised terms used but not defined in this announcement shall
have the meaning given to them in the announcement of the
Fundraising made by the Company on 18 October 2024.
For
further information:
Oncimmune Holdings plc
contact@oncimmune.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
Geoff Nash, Callum Davidson, Trisyia
Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist
Sales)
Ondraya Swanson (ECM)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King, Dan Bate
+44 (0)20 3829 5000
The
notifications set out below is provided in accordance with the
requirements of the EU Market Abuse Regulation.
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name:
|
Alistair Macdonald
|
|
1.
|
Reason for the notification
|
|
a)
|
Position/status:
|
Chairman
|
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name:
|
Oncimmune Holdings plc
|
|
b)
|
LEI:
|
213800HCYIWT6YPI1I02
|
|
3.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence each
("Ordinary Shares")
GB00BYQ94H38
|
|
b)
|
Nature of the
transaction:
|
Purchase of new ordinary
shares
|
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
15.0 pence
|
100,000
|
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Aggregated Price:
|
Single transaction as in 3 c)
above
|
|
e)
|
Date of the transaction:
|
23 October 2024
|
|
f)
|
Place of the transaction:
|
AIM, London Stock Exchange
(XLON)
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name:
|
Martin Gouldstone
|
|
1.
|
Reason for the notification
|
|
a)
|
Position/status:
|
Chief Executive Officer
|
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name:
|
Oncimmune Holdings plc
|
|
b)
|
LEI:
|
213800HCYIWT6YPI1I02
|
|
3.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence each
("Ordinary Shares")
GB00BYQ94H38
|
|
b)
|
Nature of the
transaction:
|
Purchase of new ordinary
shares
|
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
15.0 pence
|
66,667
|
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Aggregated Price:
|
Single transaction as in 3 c)
above
|
|
e)
|
Date of the transaction:
|
23 October 2024
|
|
f)
|
Place of the transaction:
|
AIM, London Stock Exchange
(XLON)
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name:
|
John Goold
|
|
1.
|
Reason for the notification
|
|
a)
|
Position/status:
|
Non-Executive Director
|
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name:
|
Oncimmune Holdings plc
|
|
b)
|
LEI:
|
213800HCYIWT6YPI1I02
|
|
3.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence each
("Ordinary Shares")
GB00BYQ94H38
|
|
b)
|
Nature of the
transaction:
|
Purchase of new ordinary
shares
|
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
15.0 pence
|
333,333
|
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Aggregated Price:
|
Single transaction as in 3 c)
above
|
|
e)
|
Date of the transaction:
|
23 October 2024
|
|
f)
|
Place of the transaction:
|
AIM, London Stock Exchange
(XLON)
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name:
|
Martin Gouldstone
|
|
1.
|
Reason for the notification
|
|
a)
|
Position/status:
|
Chief Executive Officer
|
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name:
|
Oncimmune Holdings plc
|
|
b)
|
LEI:
|
213800HCYIWT6YPI1I02
|
|
3.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence each
("Ordinary Shares")
GB00BYQ94H38
|
|
b)
|
Nature of the
transaction:
|
Waiver of options
|
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
16.95 pence
|
589,971
|
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Aggregated Price:
|
Single transaction as in 3 c)
above
|
|
e)
|
Date of the transaction:
|
8 November 2024
|
|
f)
|
Place of the transaction:
|
Outside a trading venue
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name:
|
Martin Hudson
|
|
1.
|
Reason for the notification
|
|
a)
|
Position/status:
|
Finance Director
|
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name:
|
Oncimmune Holdings plc
|
|
b)
|
LEI:
|
213800HCYIWT6YPI1I02
|
|
3.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence each
("Ordinary Shares")
GB00BYQ94H38
|
|
b)
|
Nature of the
transaction:
|
Waiver of options
|
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
26.6 pence
|
105,263
|
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Aggregated Price:
|
Single transaction as in 3 c)
above
|
|
e)
|
Date of the transaction:
|
8 November 2024
|
|
f)
|
Place of the transaction:
|
Outside a trading venue
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name:
|
Martin Gouldstone
|
|
1.
|
Reason for the notification
|
|
a)
|
Position/status:
|
Chief Executive Officer
|
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name:
|
Oncimmune Holdings plc
|
|
b)
|
LEI:
|
213800HCYIWT6YPI1I02
|
|
3.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence each
("Ordinary Shares")
GB00BYQ94H38
|
|
b)
|
Nature of the
transaction:
|
Grant of options
|
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
15 pence
|
5,588,661
|
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Aggregated Price:
|
Single transaction as in 3 c)
above
|
|
e)
|
Date of the transaction:
|
8 November 2024
|
|
f)
|
Place of the transaction:
|
Outside a trading venue
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name:
|
Martin Hudson
|
|
1.
|
Reason for the notification
|
|
a)
|
Position/status:
|
Finance Director
|
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name:
|
Oncimmune Holdings plc
|
|
b)
|
LEI:
|
213800HCYIWT6YPI1I02
|
|
3.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence each
("Ordinary Shares")
GB00BYQ94H38
|
|
b)
|
Nature of the
transaction:
|
Grant of options
|
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
15 pence
|
3,353,197
|
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Aggregated Price:
|
Single transaction as in 3 c)
above
|
|
e)
|
Date of the transaction:
|
8 November 2024
|
|
f)
|
Place of the transaction:
|
Outside a trading venue
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHFFLFFZFLFFBE
Oncimmune (LSE:ONC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Dec 2023 to Dec 2024
